Exelixis News, Exelixis Quote, EXEL Quote

Exelixis (NQ:EXEL) Delayed: 51.60 +3.06 (6.30%)

Prev. Close

$48.54

Today 6M 1Y 5Y

Open

$48.62

52 Wk High

$17.00

52 Wk Low

$3.55

Day High

$51.63

Day Low

$48.10

P/E

N/A

EPS

$-1.33

Volume

2,977,816

Friends, Peers and Foes (?): GILD, LEGN, ONC, NTRA, ACAD (more...)

ALERTS | RSS

Jun 1, 2026 04:16 PM Form 144 EXELIXIS, INC. Filed by: Eckhardt Sue Gail
Jun 1, 2026 04:06 PM Form 144 EXELIXIS, INC. Filed by: WYSZOMIERSKI JACK L
May 30, 2026 10:00 AM Exelixis reports Cabometyx trial results for neuroendocrine tumors
May 30, 2026 10:00 AM Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
May 29, 2026 05:44 PM Form 4 EXELIXIS, INC. For: May 27 Filed by: PAPADOPOULOS STELIOS
May 29, 2026 05:44 PM Form 4 EXELIXIS, INC. For: May 27 Filed by: Eckhardt Sue Gail
May 29, 2026 05:44 PM Form 4 EXELIXIS, INC. For: May 27 Filed by: Heyman Tomas J.
May 29, 2026 05:43 PM Form 4 EXELIXIS, INC. For: May 27 Filed by: Smith Julie
May 29, 2026 05:43 PM Form 4 EXELIXIS, INC. For: May 27 Filed by: Freire Maria C
May 29, 2026 05:43 PM Form 4 EXELIXIS, INC. For: May 27 Filed by: Beckerle Mary C

Entities mentioned with EXEL

View All Entities